A Study of L-735,524 in HIV-Positive Children and Adolescents
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, and plasma concentration profiles of indinavir sulfate
( MK-639; Crixivan ) in HIV-seropositive older children and adolescents. To compare the
plasma concentration profile after the initial dose with data from a historical group of
adults. To obtain preliminary data on antiviral activity of MK-639.